158 related articles for article (PubMed ID: 34885014)
1. Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase
Crosnier A; Abbara C; Cellier M; Lagarce L; Babin M; Bourneau-Martin D; Briet M
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885014
[TBL] [Abstract][Full Text] [Related]
2. Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC.
Waliany S; Zhu H; Wakelee H; Padda SK; Das M; Ramchandran K; Myall NJ; Chen T; Witteles RM; Neal JW
J Thorac Oncol; 2021 Dec; 16(12):2029-2039. PubMed ID: 34418561
[TBL] [Abstract][Full Text] [Related]
3. Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
Huang J; Meng L; Yang B; Sun S; Luo Z; Chen H
Sci Rep; 2020 Mar; 10(1):4803. PubMed ID: 32179761
[TBL] [Abstract][Full Text] [Related]
4. Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS).
Anand K; Ensor J; Trachtenberg B; Bernicker EH
JACC CardioOncol; 2019 Dec; 1(2):172-178. PubMed ID: 34396179
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
6. Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase
Cellier M; Bourneau-Martin D; Abbara C; Crosnier A; Lagarce L; Garnier AS; Briet M
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046701
[TBL] [Abstract][Full Text] [Related]
7. Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase
Noseda R; Bedussi F; Gobbi C; Ceschi A; Zecca C
J Headache Pain; 2024 Jan; 25(1):10. PubMed ID: 38243189
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
9. Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database.
Mettler C; Monnet D; Kramkimel N; Tréluyer JM; Mouthon L; Brézin A; Dupin N; Valnet-Rabier MB; Chouchana L; Terrier B
Ophthalmology; 2021 Dec; 128(12):1748-1755. PubMed ID: 34000304
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase).
Niimura T; Miyata K; Hamano H; Nounin Y; Unten H; Yoshino M; Mitsuboshi S; Aizawa F; Yagi K; Koyama T; Goda M; Kanda Y; Izawa-Ishizawa Y; Zamami Y; Ishizawa K
Drug Saf; 2023 Jun; 46(6):545-552. PubMed ID: 37106270
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced vitiligo: a case/non-case study in Vigibase
Anthony N; Bourneau-Martin D; Ghamrawi S; Lagarce L; Babin M; Briet M
Fundam Clin Pharmacol; 2020 Dec; 34(6):736-742. PubMed ID: 32246859
[TBL] [Abstract][Full Text] [Related]
12. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
13. Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study.
Zhuang W; Lu M; Wu Y; Chen Z; Wang M; Wang X; Guan S; Lin W
Clin Drug Investig; 2023 Dec; 43(12):949-962. PubMed ID: 37995087
[TBL] [Abstract][Full Text] [Related]
14. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
15. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
Saint-Gerons DM; Tabarés-Seisdedos R
Eur J Clin Pharmacol; 2021 Oct; 77(10):1513-1521. PubMed ID: 33938974
[TBL] [Abstract][Full Text] [Related]
16. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database.
Pugi A; Bonaiuti R; Maggini V; Moschini M; Tuccori M; Leone R; Rossi M; Motola D; Piccinni C; Ferrazin F; Sottosanti L; Mugelli A; Vannacci A; Lapi F
Am J Health Syst Pharm; 2013 Jun; 70(12):1039-46. PubMed ID: 23719881
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
[TBL] [Abstract][Full Text] [Related]
18. Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Zhuang W; Xu J; Wu Y; Yang J; Lin X; Liao Y; Wan J; Weng L; Lin W
Br J Clin Pharmacol; 2023 Sep; 89(9):2830-2842. PubMed ID: 37170890
[TBL] [Abstract][Full Text] [Related]
19. Cataracts and statins. A disproportionality analysis using data from VigiBase.
Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R
Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database.
de Filippis R; Kane JM; Arzenton E; Moretti U; Raschi E; Trifirò G; Barbui C; De Fazio P; Gastaldon C; Schoretsanitis G
Drug Saf; 2024 May; ():. PubMed ID: 38722481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
